Table 3.
Effects of MiPo supplementation on high-density lipoproteins (HDL) size distribution, determined by protein.
| HDL Subclasses (%) | Sample Time (n = 11) | |||
|---|---|---|---|---|
| 0 h | 4 h | 8 h | ||
| n = 11 | ||||
| HDL2b | Pre | 30.8 (15.9–35.0) | 31.5 (16.9–40.3) a | 38.6 (18.8–42.3) a |
| Post | 31.5 (17.3–40.3) a | 32.8 (19.3–40.7) b | 31.7 (18.2–42.1) | |
| HDL2a | Pre | 14.3 (10.9–16.4) | 15.0 (10.9–16.6) | 16.0 (12.5–18.7) |
| Post | 15.0 (12.3–17.9) | 14.6 (12.4–16.6) | 14.7 (10.6–16.9) | |
| HDL3a | Pre | 31.0 (27.8–35.9) | 29.2 (27.3–33.5) | 28.3 (25.9–32.8) a |
| Post | 27.7 (26.5–34.1) a | 29.5 (24.7–34.1) | 29.2 (26.0–33.3) | |
| HDL3b | Pre | 16.9 (12.5–21.8) | 14.1 (10.2–21.5) | 10.4 (7.8–21.2) a |
| Post | 14.7 (10.0–21.8) | 15.7 (8.2–25.6) | 15.3 (8.8–23.2) | |
| HDL3c | Pre | 6.2 (4.6–12.3) | 6.4 (3.4–19.3) | 4.4 (1.3–15.1) |
| Post | 5.1 (2.6–10.8) | 5.5 (2.3–16.8) | 7.9 (1.2–21.3) c | |
Data are expressed as the median (interquartile range) percentage of protein associated with each HDL subclass relative to the total HDL protein, determined during the pre- and post-supplementation periods with MiPo. Wilcoxon test, a p ≤ 0.05 vs. 0 h pre-treatment, b p ≤ 0.05 vs. 4 h pre-treatment, c p ≤ 0.05 vs. 8 h pre-treatment.